Two different characteristics and prognosis of grade 3 gastroenteropancreatic neuroendocrine tumors

dogan, ender; Ozkan, Metin; Inanc, Mevlude; TUTUS, AHMET; Öztürk, Figen; Can Sezgin, Gülten; Gürsoy, Sebnem; yurci, alper; bayram, fahri; Abdulrezzak, Ummuhan; Sözüer, Erdoğan Mütevelli

doi:10.5455/annalsmedres.2023.01.017

Two different characteristics and prognosis of grade 3 gastroenteropancreatic neuroendocrine tumors

Ender DOĞAN, (Kayseri Şehir Eğitim ve Araştırma Hastanesi, Tıbbi Onkoloji Kliniği, Kayseri, Türkiye)

Metin ÖZKAN, (Erciyes Üniversitesi, Tıp Fakültesi, Tıbbi Onkoloji Anabilim Dalı, Kayseri, Türkiye)

Mevlüde İNANÇ, (Erciyes Üniversitesi, Tıp Fakültesi, Tıbbi Onkoloji Anabilim Dalı, Kayseri, Türkiye)

ÜMMÜHAN ABDÜLREZZAK, (Erciyes Üniversitesi, Tıp Fakültesi, Nükleer Tıp Anabilim Dalı, Kayseri, Türkiye)

Ahmet TUTUŞ, (Erciyes Üniversitesi, Tıp Fakültesi, Nükleer Tıp Anabilim Dalı, Kayseri, Türkiye)

Figen ÖZTÜRK, (Erciyes Üniversitesi, Tıp Fakültesi, Patoloji Anabilim Dalı, Kayseri, Türkiye)

Erdoğan SÖZÜER, (Erciyes Üniversitesi, Tıp Fakültesi, Genel Cerrahi Anabilim Dalı, Kayseri, Türkiye)

Gülten Can SEZGİN, (Erciyes Üniversitesi, Tıp Fakültesi, Gastroenteroloji Anabilim Dalı, Kayseri, Türkiye)

Şebnem GÜRSOY, (Erciyes Üniversitesi, Tıp Fakültesi, Gastroenteroloji Anabilim Dalı, Kayseri, Türkiye)

Alper YURCİ, (Erciyes Üniversitesi, Tıp Fakültesi, Gastroenteroloji Anabilim Dalı, Kayseri, Türkiye)

Fahri BAYRAM, (Erciyes Üniversitesi, Tıp Fakültesi, Endokrinoloji Anabilim Dalı, Kayseri, Türkiye)

Diğer Yazarlar

Annals of Medical Research

4 0

Yıl: 2023 Cilt: 30 Sayı: 6 Sayfa Aralığı: 666 - 670 Metin Dili: İngilizce DOI: 10.5455/annalsmedres.2023.01.017 İndeks Tarihi: 24-07-2023

Two different characteristics and prognosis of grade 3 gastroenteropancreatic neuroendocrine tumors

Öz:

Aim: Grade 3 gastroenteropancreatic neuroendocrine tumors (GEPNETs) are not a ho mogenous group, and this work aims at determining clinicopathologic, survival and prog nostic differences in metastatic grade 3 GEPNETs with the help of Ki-67(mitotic index) and GA-68 PET CT/octreoscan. Materials and Methods: Patients diagnosed with metastatic grade 3 GEPNETs were divided into two groups based on the Ki-67 cut-off point, 47, as Ki-67 low and high. Again, the patients were divided into two groups according to scan positivity, and all four groups were compared on the basis of clinicopathologic characteristics, survival and prognostic factors. Results: Twenty-six patients were included in the study. The median overall survival in low group was 20 months and 10 months in high group (p=0.321). Lower Ki-67 scan positive group had longer overall survival than lower Ki-67 scan negative group (NR vs 3 months, respectively, p=0.067). In the high Ki-67 group, the median overall survival was longer in scan positive than negative group (10 vs 9, respectively, p=0.956). Conclusion: The median overall survival was longer in patients with low Ki-67 levels compared to high Ki-67 levels. The best overall survival was in low Ki-67 and scan positive group.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Rindi G, Arnold R, Bosman FT, Capella C, Klimstra DS, Klop pel G, et al. Nomenclature and classification of digestive neu roendocrine tumours; in Bosman TF, Carneiro F, Hruban RH, Theise ND (eds): World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of the Diges tive System. Lyon, International Agency for Research on Cancer (IARC) Press, 2010, pp 10–12.
2. Yalcin S, Bayram F, Erdamar S, Kucuk O, Oruc N, Coker A et al, Gastroenteropancreatic neuroendocrine tumors: recom mendations of Turkish multidisciplinary neuroendocrine tumor study group on diagnosis, treatment and follow-up, Arch Med Sci 2017; 13, 2: 271–282.
3. Heetfeld M, Chougnet CN, Olsen IH, Rinke A, Borbath I, Cre spo G, et al; other Knowledge Network members: Characteris tics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer 2015; 22: 657– 664.
4. Fazio N, Millione M, Heterogenity of grade 3 gastroenteropan creatic neuroendocrine carcinomas: New insights and treatment implications, Cancer Treatment Reviews:50 (2016); 61-67.
5. Vilar E, Salazar R, Perez-Garcia J, Cortes J, Oberg K & Tabernero J, Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocrine-Related Cancer, 2007; 14 221–232.
6. Velayoudom-Cephise FL, Duvillard P, Foucan L, Hadoux J, Chougnet CN, Leboulleux S, et al. 2013 Are G3 ENETS neuroen docrine neoplasms heterogeneous? Endocrine-Related Cancer 20 649–657.
7. Milione M, Maisonneuve P, Spada F, Pellegrinelli A, Spaggiari P, Albarello L et al. The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morpho logical Differentiation and Proliferation Identify Different Prog nostic Categories, Neuroendocrinology 2017;104:85–93.
8. Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufie P, Apari cio T et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. British Journal of Cancer 1999; 81 1351–1355.
9. Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Oster lund P, et al: Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neu roendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol 2013;24:152–160.
10. Lloyd RV, Osamura RY, Klöppel G, and Rosai J, WHO Classi fication of Tumours of Endocrine Organs, IARC, Lyon, France, 4th edition, 2017.
11. Tang LH, Basturk O, Sue JJ, and Klimstra DS, “A practi cal approach to the classification of WHO Grade 3 (G3) well differentiated neuroendocrine tumor (WD-NET) and poorly dif ferentiated neuroendocrine carcinoma (PDNEC) of the pan creas,” The American Journal of Surgical Pathology, vol. 40, no. 9, pp. 1192–1202, 2016.
12. Papotti M, Bongiovanni M, Volante M, Allia E, Landolfi S, Hel boe L et al. Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors: a correlative immunohistochemical and reverse-transcriptase poly merase chain reaction analysis. Virchows Arch. 2002;440:461– 475.
13. Cakir M, Dworakowska A and Grossman A., “Somatostatin re ceptor biology in neuroendocrine and pituitary tumours: part 2 – clinical implications, J Cell Mol Med. 2010 Nov; 14(11): 2585– 2591.
14. Bombardieri E, Ambrosini V,Aktolun C, Baum RP,Bishof Delaloye A, Del Vecchio S et al. 111In-pentetreotide scintigra phy: procedure guidelines for tumour imaging Eur J Nucl Med Mol Imaging (2010) 37:1441–1448).
15. Hofman MS, Lau WFE and Hicks RJ, “Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, nor mal patterns, pearls, and pitfalls in interpretation,” Radiograph ics, vol. 35, no. 2, pp. 500–516, 2015.
16. Fitzgerald TL, Mosquera C, Lea CS, McMullen M. Primary Site Predicts Grade for Gastroenteropancreatic Neuroendocrine Tu mors., Am Surg. 2017 Jul 1;83(7):799-803.
17. Hofman MS, Hicks RJ. Changing paradigms with mo¬lecular imaging of neuroendocrine tumors. Discov Med 2012;14(74):71– 81.
18. Liverani C, Bongiovanni A, Mercatali L , Foca F, Pieri F, De Vita A , Spadazzi C et al, Grading of Neuroendocrine Carcino mas: Correlation of 68Ga-PET/CT Scan with Tissue Biomark ers, Disease Markers,2018, Article ID 6878409, 8 pages.
19. Kowalski J, Henze M, Schuhmacher J, Macke HR, Hofmann M, Haberkorn U. Evaluation of positron emission tomography imag ing using [68Ga]-DOTA-D Phe(I)-Tyr(3)-Octreotide in compar ison to [111In]-DTPAOC SPECT. First results in patients neu roendocrine tumors. Mol Imaging Biol 2003;5:42-48.
20. E Baudin, A Gigliottil, M Ducreux, J Ropers, E Comoy, JC Sabourinet al. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours, Britsh Journal of Can cer(1998) 78(8). 1102-1107.

APA	dogan e, Ozkan M, Inanc M, Abdulrezzak U, TUTUS A, Öztürk F, Sözüer E, Can Sezgin G, Gürsoy S, yurci a, bayram f (2023). Two different characteristics and prognosis of grade 3 gastroenteropancreatic neuroendocrine tumors. , 666 - 670. 10.5455/annalsmedres.2023.01.017
Chicago	dogan ender,Ozkan Metin,Inanc Mevlude,Abdulrezzak Ummuhan,TUTUS AHMET,Öztürk Figen,Sözüer Erdoğan Mütevelli,Can Sezgin Gülten,Gürsoy Sebnem,yurci alper,bayram fahri Two different characteristics and prognosis of grade 3 gastroenteropancreatic neuroendocrine tumors. (2023): 666 - 670. 10.5455/annalsmedres.2023.01.017
MLA	dogan ender,Ozkan Metin,Inanc Mevlude,Abdulrezzak Ummuhan,TUTUS AHMET,Öztürk Figen,Sözüer Erdoğan Mütevelli,Can Sezgin Gülten,Gürsoy Sebnem,yurci alper,bayram fahri Two different characteristics and prognosis of grade 3 gastroenteropancreatic neuroendocrine tumors. , 2023, ss.666 - 670. 10.5455/annalsmedres.2023.01.017
AMA	dogan e,Ozkan M,Inanc M,Abdulrezzak U,TUTUS A,Öztürk F,Sözüer E,Can Sezgin G,Gürsoy S,yurci a,bayram f Two different characteristics and prognosis of grade 3 gastroenteropancreatic neuroendocrine tumors. . 2023; 666 - 670. 10.5455/annalsmedres.2023.01.017
Vancouver	dogan e,Ozkan M,Inanc M,Abdulrezzak U,TUTUS A,Öztürk F,Sözüer E,Can Sezgin G,Gürsoy S,yurci a,bayram f Two different characteristics and prognosis of grade 3 gastroenteropancreatic neuroendocrine tumors. . 2023; 666 - 670. 10.5455/annalsmedres.2023.01.017
IEEE	dogan e,Ozkan M,Inanc M,Abdulrezzak U,TUTUS A,Öztürk F,Sözüer E,Can Sezgin G,Gürsoy S,yurci a,bayram f "Two different characteristics and prognosis of grade 3 gastroenteropancreatic neuroendocrine tumors." , ss.666 - 670, 2023. 10.5455/annalsmedres.2023.01.017
ISNAD	dogan, ender vd. "Two different characteristics and prognosis of grade 3 gastroenteropancreatic neuroendocrine tumors". (2023), 666-670. https://doi.org/10.5455/annalsmedres.2023.01.017

APA	dogan e, Ozkan M, Inanc M, Abdulrezzak U, TUTUS A, Öztürk F, Sözüer E, Can Sezgin G, Gürsoy S, yurci a, bayram f (2023). Two different characteristics and prognosis of grade 3 gastroenteropancreatic neuroendocrine tumors. Annals of Medical Research, 30(6), 666 - 670. 10.5455/annalsmedres.2023.01.017
Chicago	dogan ender,Ozkan Metin,Inanc Mevlude,Abdulrezzak Ummuhan,TUTUS AHMET,Öztürk Figen,Sözüer Erdoğan Mütevelli,Can Sezgin Gülten,Gürsoy Sebnem,yurci alper,bayram fahri Two different characteristics and prognosis of grade 3 gastroenteropancreatic neuroendocrine tumors. Annals of Medical Research 30, no.6 (2023): 666 - 670. 10.5455/annalsmedres.2023.01.017
MLA	dogan ender,Ozkan Metin,Inanc Mevlude,Abdulrezzak Ummuhan,TUTUS AHMET,Öztürk Figen,Sözüer Erdoğan Mütevelli,Can Sezgin Gülten,Gürsoy Sebnem,yurci alper,bayram fahri Two different characteristics and prognosis of grade 3 gastroenteropancreatic neuroendocrine tumors. Annals of Medical Research, vol.30, no.6, 2023, ss.666 - 670. 10.5455/annalsmedres.2023.01.017
AMA	dogan e,Ozkan M,Inanc M,Abdulrezzak U,TUTUS A,Öztürk F,Sözüer E,Can Sezgin G,Gürsoy S,yurci a,bayram f Two different characteristics and prognosis of grade 3 gastroenteropancreatic neuroendocrine tumors. Annals of Medical Research. 2023; 30(6): 666 - 670. 10.5455/annalsmedres.2023.01.017
Vancouver	dogan e,Ozkan M,Inanc M,Abdulrezzak U,TUTUS A,Öztürk F,Sözüer E,Can Sezgin G,Gürsoy S,yurci a,bayram f Two different characteristics and prognosis of grade 3 gastroenteropancreatic neuroendocrine tumors. Annals of Medical Research. 2023; 30(6): 666 - 670. 10.5455/annalsmedres.2023.01.017
IEEE	dogan e,Ozkan M,Inanc M,Abdulrezzak U,TUTUS A,Öztürk F,Sözüer E,Can Sezgin G,Gürsoy S,yurci a,bayram f "Two different characteristics and prognosis of grade 3 gastroenteropancreatic neuroendocrine tumors." Annals of Medical Research, 30, ss.666 - 670, 2023. 10.5455/annalsmedres.2023.01.017
ISNAD	dogan, ender vd. "Two different characteristics and prognosis of grade 3 gastroenteropancreatic neuroendocrine tumors". Annals of Medical Research 30/6 (2023), 666-670. https://doi.org/10.5455/annalsmedres.2023.01.017